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Do fatigue and UDCA therapy truly have independent effects
on mortality in PBC?
To the Editor:
We read with interest the paper by Jones et al. [1] regarding the
impact of fatigue and ursodeoxycholic acid (UDCA) treatment on
mortality in PBC. The authors are to be congratulated on their
accrual and close follow up of a well characterised group of
patients and their efforts have certainly expanded further our
understanding of the natural history and the effects of pharmaco-
logical interventions in PBC.
Nonetheless, caution must be exercised when evaluating their
dataset and conclusions, particularly in respect of the indepen-
dent effect of fatigue and UDCA usage on mortality for the follow-
ing reasons.
Firstly, whilst on univariate analysis both the presence of fati-
gue (which, importantly was identiﬁed here as a categorical var-
iable) and lack of use of UDCA were associated with increased
mortality, only 43 deaths were recorded. Consequently, the anal-
ysis of seven different variables in the Cox regression model is
possibly excessive and could lead to statistical errors in its output
as the ‘‘rule of thumb’’ of regression analysis has historically been
a minimum of 10 outcome events per variable. However, recent
reports suggesting the use of 5–9 outcomes per variable only
uncommonly lead to statistical error, though is slightly more
common with Cox models [2].
Secondly, fatigue, previously identiﬁed as categorical (present
or absent), is now interpreted as a linear score (based on the FIS)
as part of the Cox model. Therefore, although a 1 point increase in
the FIS is independently associated with an increased mortality
(risk ratio 1.008), how the presence (or otherwise) of fatigue
affects mortality in an independent model is not certain.
Thirdly, and perhaps most crucially, in this model, UDCA ther-
apy was not independently predictive of improved mortality at
all with a risk ratio of 0.728 (95% CI 0.370–1.432) p = 0.357. This
issue is of fundamental importance as it is at variance with the
very title of the manuscript.
On a ﬁnal note, the results in Table 1 suggests a possible typo-
graphical error in regard to the effect of age on mortality. The ini-
tial B value would suggest an increased risk for age and,
therefore, a risk ratio of >1, especially given the highly signiﬁcant
p value. However, the risk ratio of 0.728% and 95% CI of 0.37–
1.432 cannot provide such a highly signiﬁcant p value, given
the 95% CI clearly crosses 1.
In summary, whilst it remains possible that fatigue is indepen-
dently associated with increased mortality in PBC, the data pre-
sented by Jones et al. in its published format does not prove
that this is the case in respect of the presence or otherwise of fati-
gue. Furthermore, the use of UDCA therapy cannot be said to have
any independent effect on mortality, based on the published data.
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Letters to the Editor
OpReply to: Do fatigue and UDCA therapy truly have independent
effects on mortality in PBC?To the Editor:
We thank Drs. Yousuf and Yeoman for their appreciation of our
work and interest in our recent paper [1] regarding the impact
of fatigue and ursodeoxycholic acid (UDCA) treatment on mortal-
ity in PBC. Although they raise some interesting points, we
believe they may not fully understand the conclusions we made
in our paper. This is the largest series of patients with PBC fol-
lowed up for a considerable period of time, and this cohort hasJournal of Hepatology
en access under CC BY-NC-ND license.provided important insights into the true impact that fatigue
has on not only quality of life but also length of life.
Yousuf and Yeoman are correct, COX models can theoretically
be limited in their interpretation as the number of variables is
increased. If we had used this as our only analysis, we may have
agreed with them; however, combined with the Kaplan Meier
and Log Rank Test Analysis, which conﬁrm the relationship
between fatigue and mortality, we believe this enhances the2011 vol. 55 j 729–733
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power of the COX models considerably and should be interpreted
as underlining our ﬁndings.
In order to perform the Kaplan Meier analysis it was necessary
to dicotomise the groups into those with and without fatigue. The
rationale for this was described fully in the original description of
the cohort [2]. The COX model allowed us to explore the absolute
level of FIS score. Both analyses conﬁrmed the relationship
between fatigue and mortality and, therefore, we cannot under-
stand how Yousaf and Yeoman can now suggest ‘‘how the pres-
ence (or otherwise) of fatigue affects mortality in an
independent model is not certain’’.
The authors are correct, in the COX model UDCA therapy was
not independently predictive of improved mortality and on the
basis of this they refute our conclusions regarding UDCA. We
believe inclusion of categorical data into a COX model is a blunt
instrument and we would direct Yousuf and Yeoman to the other
analyses in the results section which clearly show that the effect
that UDCA response has upon mortality is clearly independent of
the effect that fatigue status has. This is an important message for
clinicians managing patients with PBC in that it conﬁrms that
non-fatigued patients who are UDCA responders are at very low
risk. This is one of the key messages from the paper.
In summary, we question what further data the authors con-
sider required to conﬁrm to them that it has now gone from
beyond the ‘‘possible that fatigue is independently associated with
increased mortality in PBC’’ if they believe that our well charac-
terised comprehensively collected geographically deﬁned cohort
does not ‘‘prove that this is the case in respect of the presenceSLC40A1-R178G mutation
To the Editor:
In their excellent systematic meta-analysis on the ferroportin
disease, recently published in the Journal of Hepatology, Mayr
et al. present in detail all the described SLC40A1 gene alterations
and their relationship with disease phenotype [1]. The prevalence
of these alterations in the general population is also presented,
indicating that a few of them are polymorphisms with an
unknown, as yet, biological signiﬁcance.
Amongst these alterations, the authors include the mutation
SLC40A1-R178G, described by us in a Greek family with
ferroportin disease [2], despite the fact that they refer regarding
this mutation (Table 3), obviously by mistake, to another
publication. To this end, it is interesting to present information
derived from the 2-year follow-up of the affected members of
this family, as well as the data missing from the literature popu-
lation that we have acquired in the mean time, indicating that the
SLC40A1-R178G mutation is not a polymorphism. Instead, they
support our position that it represents a novel mutation resulting
in classical ferroportin disease with a mild, and rather variable,
phenotype.
In our previous publication, the SLC40A1-R178G mutation was
found to be responsible for a classical ferroportin disease pheno-
type in a 25-year-old female [2], who remains in excellent condi-
tion being subjected to periodical venesections every three
730 Journal of Hepatology 2or otherwise of fatigue’’. Furthermore we would suggest that
we clearly show, albeit in a small cohort, that response to UDCA
therapy has an effect on mortality.
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months. Examining the family tree, we detected the same muta-
tion in the proband’s 53-year-old mother, presenting with slight
hyperferritinemia and liver hemosiderosis of moderate degree.
During the follow-up, her hyperﬁrretinemia worsened, necessi-
tating therapeutic venesections. The SLC40A1-R178G mutation
was also detected in the proband’s 87-year-old grandfather
who displayed low transferrin saturation, but not hyperferritin-
emia. Because of his old age, this patient, the oldest one in the lit-
erature diagnosed with ferroportin disease, was not submitted to
further evaluation regarding the possible coexistence of iron deﬁ-
ciency. Two years after the diagnosis, he remains alive without
needing venesections.
Following this atypical presentation of ferroportin disease and
considering that the SLC40A1-R178G mutation had not been
observed in large comprehensive population studies [3–5], we
questioned whether it was a functional polymorphism prevalent
in the Greek population.
To this end, we analyzed 253 bone marrow donors (male/
female: 123/130, mean age: 34.7 years, range: 21–60) from Cen-
tral Greece area. All subjects provided written informed consent,
while the study was conducted in accordance with the principles
of Helsinki declaration and was approved by the Institutional
Review Board of the University Hospital of Larissa, Greece. Geno-
mic DNA was extracted from peripheral blood using the QIAamp
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